Iron showdown: which anemia drug works best for kidney patients?
NCT ID NCT06994065
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at 128 adults with chronic kidney disease (not on dialysis) who also had iron-deficiency anemia. Researchers compared two intravenous iron treatments—ferric carboxymaltose and iron sucrose—to see which raises hemoglobin and iron levels better and with fewer side effects. Participants received a dose based on their iron deficit and were followed for 56 days.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Ferric carboxymaltose (FCM) and iron sucrose
- What this could lead to
- If it works, this could point toward a more effective or convenient option for treating iron-deficiency anemia in people with chronic kidney disease who are not on dialysis.
- What could go wrong
- This is a small, completed trial (128 people) comparing two existing drugs, so it is not testing a new breakthrough. Results may not apply to all kidney patients, and both treatments carry risks like allergic reactions or low blood pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
128 people
The number who actually took part.
- Started
-
Apr 2025
- Finished
-
Nov 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Outpatients * Between age 18-85 years * Patients diagnosed with Chronic kidney disease having eGFR of less than 60 ml/kg/1.73m2 (not on maintenance dialysis) Exclusion Criteria: * Patients on maintenance dialysis * Patients with concomitant B12 or folate deficiency * Patients receiving ESA therapy * Patients with prior Iron replacement therapy within preceding 2 weeks * Patients receiving blood transfusions within preceding 3 months * Pregnant Females * Patients with Upper GI Bleeding * Patients with history of hematologic disorders, active malignancy or chronic inflammatory conditions like tuberculosis or ulcerative colitis
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Iron deficiency anemia associated with non-dialysis dependent chronic kidney disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sindh Institute of Urology and Transplantaion
Karachi, Sindh, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.